02/04/2026
Mounjaro has arrived at GLO Clinic, a new, clinically backed option to support weight management for suitable patients.
This isn’t a quick fix or a trend. It’s a medical treatment that works alongside lifestyle, education, and ongoing support because sustainable results are built, not rushed.
As always, suitability matters.
Mandatory Statement in images, results may vary. Book a consultation to see if it’s right for you.
Mounjaro® must be used in addition to a reduced-calorie diet and increased physical activity for persons living with obesity or overweight with at least 1 weight-related comorbid condition. In people with type 2 diabetes mellitus, Mounjaro® must be used in addition to diet and exercise, and may be used in addition to other medicinal products for the treatment of type 2 diabetes, at the discretion of a New Zealand registered doctor. Mounjaro® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. Mounjaro® is also indicated in additional to diet and exercise for chronic weight management, including weight loss and weight maintenance, in adults who meet certain body mass index (BMI) criteria. Mounjaro® contains the active ingredient tirzepatide and is available in the following dose forms: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. All KwikPens contain four once weekly 0.6 mL doses of Mounjaro®. Mounjaro® has risks and benefits. Ask your doctor if Mounjaro® is right for you. Use strictly as directed. If you experience side effects, see your doctor, pharmacist, or healthcare professional. The most common side effects of Mounjaro® are nausea, diarrhoea, vomiting, and constipation. Please refer to the Mounjaro® Consumer Medicine Information available at www.medsafe.govt.nz, or in your Mounjaro® KwikPen carton before taking your medicine. Mounjaro® is an unfunded prescription medicine - payment for this medicine and any additional doctor and pharmacy fees will be required. Eli Lilly, Auckland. © 2026 Eli Lilly and Company (NZ)\Limited. MOUNJARO® and KwikPen® are registered trademarks of Eli Lilly and Company.